EHG Portfolio of Distribution Rights

Whether newly USFDA released or second-life generics, EarlyHealth ensures that our customers penetrate the right markets for the well-being of the patients unmet needs.

If you are interested to assign products for exclusive distribution, whether as unlicensed or registered for distribution, contact our Market Access team and see how we can maximize return on your asset, whilst benefiting those patients is need of treatments locally not available.

EarlyHealth Group, with its offices, warehouses and depots in Europe, Latin America, Asia and Middle East, along with partnership solutions in other territories, is well-positioned to enhance value globally through importation for named patient programs.

Through exclusive distribution and quality agreements with pharmaceutical and biotech companies, we maintain pharmacovigilance under an SDEA, and provide medical information, as well as therapy and disease awareness services.

Below is our portfolio of product distribution rights, for more information on how to access these products, contact us today.

Portfolio of Distribution Rights

Beleodaq ® by Ideogen

Beleodaq is a histone deacetylase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

Beromun ® by Boehringer Ingelheim

Beromun is used as an adjunt to surgery for resection of soft tissue sarcoma.

Colchicina Lirca ® by Recordati

Colchicina Lirca treats flare-ups (attacks) of gout.

Elocta ® by Sobi

Elocta is used for the treatment and prevention of bleeding with haemophilia A (inherited bleeding disorder caused by factor VIII deficiency).

Evoltra ® by Ideogen

Evoltra is used to treat children and adults up to 21 years of age who have acute lymphoblastic leukaemia (ALL).

Fleboside ® by ACARPIA

Fleboside is indicated for the treatment of the venous insufficiency and capillary fragility conditions, including hemorrhoids.

Fluss ® by ACARPIA

Fluss is generally prescribed to manage edema (swelling due to fluid retention) and hypertension (high blood pressure).

Kineret® by Sobi

Limican ® by ACARPIA

Limican is indicated for the treatment of vomiting and nausea caused by various factors and before or after surgery.

Orfadin® by Sobi

Orfadin is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase indicated for use as an adjunct to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1 (HT-1).

Phenergan ® by Laboratoires Famel

Phenergan (Promethazine) is a first-generation antihistamine and antiemetic used to treat allergies, insomnia, and nausea.

Seglor ® by ACARPIA

Seglor is indicated for the treatment of headache, migraine (recurrent attacks of moderate to severe headache) and vertigo.

Sidovis ® by Ideogen

Sidovis (Cidofovir) is indicated for the treatment of CMV retinitis in adults with acquired immunodeficiency syndrome (AIDS).

Trinitrina ® by ACARPIA

Trinitrina is indicated for treatment and prevention of acute angina pectoris attacks, acute pulmonary edema and pre-pulmonary edema.

Triogen ® by Ideogen

Triogen is indicated for the treatment of copper storage disease (Wilson’s disease).

Trixacar ® by Gador

Trixacar is used for the treatment of cystic fibrosis (CF).

Waylivra® by Sobi

Waylivra is used to treat familial chylomicronemia syndrome (FCS

Portfolio of
Distribution Rights